Prognostic Role of Lipoprotein(a) in Elective Percutaneous Coronary Revascularization

NCT07197242 | Not Yet Recruiting

• 1 other identifier: Lp(a) and Risk in Elective PCI
• Study Type: observational
• Target: 156
• Locations: 0 countries
• Sites: N/A

Brief Summary

The study investigates the role of Lipoprotein(a) \[Lp(a)\] levels in predicting cardiovascular risk and adverse events in patients undergoing elective percutaneous coronary intervention (PCI).

Conditions

PCI

Keywords

PCI; coronary artery disease

Outcome Measures

Primary Outcomes (1)

• Incidence of major adverse cardiovascular events (MACE)

  Incidence of all non-fatal myocardial infarction, and ischemia-driven target vessel revascularization or or definite/probable stent thrombosis.

  one year

Study Arms (1)

Adult patients (≥18 years old) undergoing elective PCI for stable coronary artery disease will form

The targeted cohort consists of men and women presenting with stable ischemic heart disease scheduled to undergo elective PCI at the Assiut University Heart Hospital cardiac catheterization unit

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

targeted cohort consists of men and women presenting with stable ischemic heart disease scheduled to undergo elective PCI at the Assiut University Heart Hospital cardiac catheterization unit. Eligible patients must provide informed consent and undergo baseline blood sampling. The study excludes patients with recent acute coronary syndrome (ACS within 30 days), cardiogenic shock, prior cardiac transplantation/LVAD, limited life expectancy from non-cardiac causes, or those enrolled in contemporary blinded clinical trials specifically for Lp(a)-lowering therapies. By selecting an elective CAD population, the study narrows focus to a lower baseline

You may qualify if:

• Adults aged 18 years or older
• Undergoing elective PCI for stable coronary artery disease
• Ability to provide informed consent
• Willingness to undergo blood sampling prior to PCI

You may not qualify if:

• Acute coronary syndrome within 30 days
• Cardiogenic shock
• Prior heart transplant or left ventricular assist device (LVAD)
• Life expectancy less than 1 year due to non-cardiac causes
• Participation in a blinded Lp(a)-lowering outcome trial at the time of enrollment

Sponsors & Collaborators

• Assiut University: lead

Related Publications (1)

• Vinci P, Di Girolamo FG, Panizon E, Tosoni LM, Cerrato C, Pellicori F, Altamura N, Pirulli A, Zaccari M, Biasinutto C, Roni C, Fiotti N, Schincariol P, Mangogna A, Biolo G. Lipoprotein(a) as a Risk Factor for Cardiovascular Diseases: Pathophysiology and Treatment Perspectives. Int J Environ Res Public Health. 2023 Sep 6;20(18):6721. doi: 10.3390/ijerph20186721.

  PMID: 37754581 BACKGROUND

MeSH Terms

Conditions

Coronary Artery Disease

Condition Hierarchy (Ancestors)

Coronary Disease; Myocardial Ischemia; Heart Diseases; Cardiovascular Diseases; Arteriosclerosis; Arterial Occlusive Diseases; Vascular Diseases

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: resident at Cardiology Department

Study Record Dates

• First Submitted: September 20, 2025
• First Posted: September 29, 2025
• Study Start (Estimated): October 1, 2026
• Primary Completion (Estimated): June 30, 2027
• Study Completion (Estimated): December 30, 2027
• Last Updated: September 29, 2025

Record last verified: 2025-09

Data Sharing

• IPD Sharing: Will not share